Burning Rock Biotech (BNR) Operating Leases (2021 - 2025)

Burning Rock Biotech's Operating Leases history runs 5 years deep, the most recent figure standing at $3.4 million for Q4 2025.

• In Q4 2025, Operating Leases fell 10.75% year-over-year to $3.4 million; the TTM figure through Dec 2025 stood at $3.4 million (down 10.75% YoY), while the FY2025 annual figure was $3.5 million, down 51.21% from the prior year.
• Operating Leases was $3.4 million for Q4 2025 at Burning Rock Biotech, up from $2.0 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $11.1 million in Q2 2024 to a low of $512494.5 in Q4 2023.
• Historically, Operating Leases has averaged $3.8 million across 5 years, with a median of $2.7 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Operating Leases tumbled 82.32% in 2023, then jumped 1387.14% in 2024.
• A 5-year view of Operating Leases shows it stood at $7.7 million in 2021, then plunged by 75.3% to $1.9 million in 2022, then plunged by 73.1% to $512494.5 in 2023, then soared by 653.92% to $3.9 million in 2024, then slipped by 10.75% to $3.4 million in 2025.
• The last three Operating Leases figures came in at $3.4 million (Q4 2025), $2.0 million (Q3 2025), and $2.5 million (Q2 2025), per Business Quant data.